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Children born with congenital heart valve defects require open-heart surgery to
implant an artificial replacement valve.

These valves are unable to grow with the

developing child and need replacing every 5 years. Tissue engineered heart valves,
capable of growing with the patient, would alleviate the need for repeat surgery. I
hypothesize chitosan and collagen possess advantageous qualities as scaffolding for a
tissue engineered heart valve. This study evaluated chitosan and collagen hydrogels as
potential scaffold materials. Chitosan scaffolds had suitable pore size/distribution and
scaffold strength; however, they were unable to sustain cell attachment or viability.
Collagen gels were assessed for compaction, mechanical properties and expression of
matrix metalloproteases in the presence or absence of biochemical and mechanical
stimuli. Pressure increased the remodeling potential. This was augmented further in the

presence of TGF-β. In conclusion, both materials have potential as scaffolding substrate
in a tissue engineered heart valve.
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CHAPTER I
INTRODUCTION AND BACKGROUND

Physiology of the Heart
The heart is a four chamber organ that is responsible for pumping hormones,
blood and nutrients throughout the body. Briefly, deoxygenated blood flows into the
right atrium from the inferior and superior vena cava.

The right atrium contracts

pumping blood through the tricuspid valve into the right ventricle. The tricuspid valve
closes to prevent backflow of blood into the right atrium. Upon filling of the right
ventricle, blood is pumped through the pulmonary valve to the lungs via the pulmonary
artery for oxygenation. The pulmonary vein returns oxygen rich blood to the left atrium.
Next, the left atrium contracts pumping blood through the mitral valve to the left
ventricle. Once the mitral valve closes, the left ventricle propels blood through the aortic
valve and to the entire body. This process, and the anatomy of the heart, is shown in
Figure 1. Before blood is expelled from the left ventricle, the aortic valve changes size
and shape (1). This finding conflicts the previous notion that the aortic valve was passive
and would open due to a pressure gradient. Once the ventricles relax, pressure in the left
ventricle drops, causing blood to flow backwards. The result of this backflow causes the
cusps to snap together, preventing regurgitation.
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Figure 1 Blood flow through the heart with oxygenated blood in red and
deoxygenated blood in blue (revolutionhealth.com)

Aortic Valve Structure
As the gateway of blood from the heart, the aortic valve is subject to many
different forces and subsequently has a structure able to withstand these loads. The aortic
valve consists of three leaflets and three sinuses. The leaflets resemble half moons thus,
they are called semilunar. The sinuses are the areas behind the leaflets. At the lower end,
the sinuses merge with the left ventricle, and the upper end is incorporated into the
ascending aorta. The sinuses are named right coronary sinus, left coronary sinus, and
noncoronary sinus.

Figure 2 shows a representation of the aortic root opened

longitudinally through the left coronary sinus. The junctions between the leaflets are
known as commissures. The leaflet commissures are formed where two leaflets insert
2

side by side along parallel lines. The sinuses come together at the commissures and
continue across the sinus rim distally into the aorta. As the ventricles contract during
systole, the three semilunar cusps of the aortic valve are pushed aside, towards the walls
of the aorta.

Figure 2 Aortic valve (a) intraleaflet triangles (b) leaflets

The aortic valve leaflets are flaps that seal the valve when it closes. Leaflets can
be broken down into three regions, as shown in Figure 2. One region is known as the
ventricularis, which is the layer that faces the left ventricle. The ventricularis comprises
approximately 20% of the total thickness of the leaflet and consists of a dense network of
collagen and elastin fibers. The middle gelatinous region of the leaflet is known as the
spongiosa. Comprising 35% of the total valve thickness, the spongiosa contains a high
concentration of glycosaminoglycans. The fibrosa, which constitutes 45% of the total
thickness, faces the aorta and is subjected to sizeable amounts of shear stress due to the
turbulent flow of blood coming from the left ventricle during systole. The fibrosa is
3

noticeably wavy as compared to the smooth ventricularis. For this reason, the fibrosa is
composed predominately of a dense network of collagen fibers and thus able to withstand
substantial amounts of stress as previously described (2). The fibrosa and ventricularis
are also preloaded because of their attachment to each other. Due to this preloading, the
fibrosa is under compression and the ventricularis is under tension (3).

Figure 3 Layers of the aortic valve: the fibrosa faces the aorta and contains
collagen fibers oriented in the circumferential direction; the spongiosa
is the middle layer and is composed of mostly proteogylcans and
glycosaminoglycans; the ventricularis faces the left ventricle and
contains collagen and elastin fibers oriented in the radial direction (3).

Cells of the Aortic Valve Leaflet
The aortic valve consists of two distinct types of cells known as valvular
interstitial cells (VICs) and endothelial cells (ECs). ECs line the surface of the leaflet and
4

create a nonthrombogenic blood-tissue interface. This interface allows ECs to regulate
inflammatory and immune responses via biochemical signaling to interstitial cells. In
addition, Filip et al. speculated that physical communication also occurs between ECs
VICs.

ECs are thought to regulate vascular tone, inflammation, thrombosis and

remodeling.

Disruption or damage to the EC monolayer is known to initiate an

inflammatory response leading to valvular disorders.
Many differences exist between valve and vascular ECs. Valvular ECs align
perpendicular to blood flow due the mechanical stress induced by the flow of blood,
while vascular ECs align parallel to blood flow. Canine valvular ECs are oriented
circumferentially across leaflets (4). In addition, aortic ECs have a distinct phenotype
and gene expression profile compared to vascular ECs exposed to the same mechanical
environment (5).

Finally, different transcriptional profiles are exhibited by ECs

harvested from the ventricularis and the fibrosa side (6).
VICs are more numerous than the previously described valvular ECs. VICs can
be present in all the layers of the leaflet with various densities, and are responsible for
organizing and remodeling matrix proteins. VICs possess a phenotypic plasticity that is
regulated by environmental matrix stimuli and soluble signals (7). VICs can be further
divided into myofibroblast, fibroblast and smooth muscle cells. The phenotypic state of
valvular interstitial cells corresponds to the remodeling demand of the tissue, and has
correlated cellular contractility to biosynthetic activity (8).

Activated VICs, or

myofibroblasts, are collagen producing cells that express contractile proteins, most
notably α-smooth muscle actin. In normal healthy valves α-smooth muscle actin is
present at low levels(9). However, valve remodeling causes VICs to express α-smooth
5

muscle actin at an elevated level (9;10). VICs assist in maintaining structural integrity of
the leaflet tissue via remodeling by protein synthesis and enzymatic degradation. In
addition fibroblasts synthesize collagen, proteoglycans, growth factors, elastin, cytokines,
fibronectin, chemokines, and matrix metalloproteases (MMPs). Valvular MMPs control
growth factor production and remodel extracellular matrix (ECM). Smooth muscle cells
are found either singly or arranged in thin bundles and have been implicated in valvular
contraction (11). Smooth muscle cells are characterized by the expression of α/β-myosin
heavy chain and α-myosin heavy chain, SM1 and SM2 respectively. Myofibroblast are
postulated to be involved in cellular contraction, migration and proliferation.
Myofibroblasts show features of both smooth muscle cells and fibroblast by expressing
contractile proteins, secreting ECM, and containing both muscle and non-muscle
regulatory and structural proteins (9;12).

Aortic Valve Disease
The aortic valve regulates blood flow from the heart to the entire body thus, a
compromise of the structure or function of this valve may have dire consequences.
Generally, the non-rheumatic diseases of the aortic valve fall into two categories. First,
aortic stenosis is known as the condition when blood flow is restricted from a constricted
valve. This form of valve disease can be seen as a congenital abnormality or can be
manifested later in the form of buildup of scar tissue and calcium. Symptoms of aortic
valve stenosis include shortness of breath, angina, dizziness, and possible sudden death
(13). A precursor to stenosis is aortic valve sclerosis (AVS). AVS is a condition of
thickening and calcification of the normal aortic valve without obstruction to the left
6

ventricular outflow track. Evidence suggests that AVS is associated with an increased
incidence of cardiovascular events, such as myocardial infarction, heart failure and stroke
(14).

The second type of aortic valve disease, aortic regurgitation, occurs when

retrograde blood is allowed back into the ventricle during diastolic filling, reducing the
net forward flow of blood. This form of valve disease is usually initiated from structural
abnormalities. Often times the aorta stretches, thus the aortic leaflets are inadequate to
prevent regurgitation. In addition to being seen individually, these two conditions can
occur simultaneously. The improper functioning of the aortic valve requires the heart
working harder to supply the body with the proper amount of oxygen and nutrients.
Similar to an athlete increasing his strength or adding muscle through strenuous training
and conditioning, so does the heart when it must overcome the shortcomings of a faulty
aortic valve.

As the heart works harder, the ventricular wall becomes thickened,

eventually leading to left ventricle hypertrophy and ultimately congestive heart failure.
Congenital cardiovascular defects occur in approximately 1 percent of all live
births and are the most common congenital malformations in newborns. Two of the more
common defects are Marfan’s Syndrome and Tetralogy of Fallot. Marfan’s Syndrome is
seen in about 1 in every 5000 births worldwide (15). The recognizable features of the
syndrome include tall stature, joint hypermobility, mitral valve prolapse and skeletal
abnormalities. Aortic dilatation leads to aortic regurgitation and ultimately to aortic
dissection, which is the most serious complication.

Another congenital heart defect,

Tetralogy of Fallot, is when four heart defects occur at birth. These defects include a
ventricular septal defect, pulmonary stenosis, right ventricular hypertrophy, and an
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overriding aorta. Both previously mentioned congenital heart defects require surgical
intervention.

Current Treatment Options
With the prevalence of aortic valve disease the necessity arises for a substitute for
these defective or faulty valves. Due to late detection and intervention, the treatment for
a diseased aortic valve is typically total replacement of the valve. More than 100,000 US
patients every year need to have their dysfunctional or diseased valves replaced (16).
Currently, a surgeon may choose to use a bioprosthetic or mechanical valve as a
treatment option depending on the specific needs of the patient.
Bioprosthetic valves are a treatment option that entails an allograft or xenograft
replacement.

Allografts are valves taken from humans and are ideal replacements

because these valves are structurally identical. When a non-viable allograft is taken from
a donor upon autopsy, the valve is treated with antibiotics to sterilize and can be stored at
4ºC for weeks. The drawback to the nonviable valves is the inability to remodel and
repair, which greatly reduces the lifetime of the replacement. A second allograft option is
to obtain a viable valve from an organ donor and cryopreserved in dimethylsulfoxide to
protect from crystallization. This form of allograft is preferred because less deterioration
has occurs. In general, allografts are preferred over xenografts; however, the supply of
allografts is limited by the amount of donors and difficulty in acquiring the proper size.
Ultimately, the supply does not meet the demand thus the need for xenografts.
Xenografts, which can be seen in Figure 4, are taken from another species, treated
and implanted into the human body. Most often porcine aortic valves are chosen for the
8

structural and hemodynamic similarities. In addition, porcine aortic valves are readily
available leading to an ample supply of replacements. Another xenograft option is a
bovine pericardial valve and is fabricated from 3 separate pieces of calf pericardium
treated in glutaraldehyde. The pieces are attached to a supporting stent and sewing cuff.
In order to implant the valve into a human, the porcine or bovine valve is crosslinked
with low concentrations of glutaraldehyde to reduce antigenicity and proteolytic
degradation that would otherwise occur following implantation into the patient.
Consequently, the treatment in glutaraldehyde kills the cells within the valve, and can
lead to calcification and stiffening causing the need for still another option of
replacement.

Since the prosthesis no longer contains living cells, the valve cannot

remodel or respond to injury as does normal, viable tissue.

Figure 4 Xenograft Options for Aortic Valve Replacement. A-B(medtronic)
C(edwards.com) Stented Porcine Xenograft (A), Non-stented Porcine
Xenograft (B), Bovine Pericardial Xenograft (C)
Another alternative for a diseased or malformed aortic valve is to undergo the
Ross Procedure. The Ross Procedure entails using the pulmonary valve of the patient, an
autograft, to replace the defected aortic valve. The pulmonary valve would then be
replaced with a cryoperserved pulmonary valve from a cadaver.
9

An advantage of the

Ross Procedure includes eliminating the risk of an immunogenic response from the
implant.

The valve is viable allowing remodeling and response to injury.

Anticoagulation therapy is not needed for this procedure allowing for an active lifestyle.
The longevity of this alternative is greater than a porcine prosthesis because the
procedure is glutaraldehyde-free.
Mechanical valves are the second replacement option. Mechanical valves are
composed of nonphysiologic biomaterials that employ a rigid, mobile occluder in a
metallic cage as in the Bjork-Shiley, Hall-Medtronic, and OmniScience valves. A second
type of tilting disk valve uses two carbon disks that are attached to a carbon ring as in the
St. Jude Medical, CarboMedics CPHV, Medical Carbon Research Institute or On-X
prosthesis. These types of aortic valve replacements can be seen in Figure 5. Pyrolytic
carbon has excellent biocompatibility with thromboresistence, high fatigue strength, and
wear resistance. The valves open and close passively due to the changes in pressure and
blood flow within the chambers of the heart. The primary drawback of mechanical valve
replacement is the patients need for lifelong anticoagulation therapy to reduce the risk of
thrombosis and thromboembolic events that result from platelet activation due to
turbulent flow through the valve (17). The turbulent flow through these mechanical
valves creates large amounts of shear on vessel walls, which damages the endothelium.
Platelets become activated and adhere when damage to the endothelium is encountered.
A thrombus soon forms restricting blood flow through the vessel.

Also, a major

limitation in pediatric patients is the valve’s inability to grow with the patient, which
necessitates multiple surgeries throughout the patient’s lifespan with an increase risk in
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mortality with each subsequent surgery.

An evaluation of current aortic valve

replacements is seen in Table 1.

A

B

C

Figure 5 Mechanical Valves. Ball and Cage (A), Bileaflet tilting disc (B),
Tilting Disc (C)
Table 1 Evaluation of current aortic valve replacements.
Mechanical
Valves
Foreign body
response
Lack of growth
Mechanical
failure
Need for life
long
anticoagulation

Xenograft

Allograft

Ross
Procedure

Foreign body response

Foreign body response

Foreign body
response

Lack of growth

Lack of growth

Short durability

Donor organ scarcity

Calcification

Rejection

Growth
potential
No rejection

Thrombosis
Tissue Engineering
Tissue engineering is an emerging field of medical science that fuses basic
engineering and biology to create new organ or tissue for implantation. This new field
offers a possible solution that would solve the short comings of current valvular treatment
11

options. As defined by Simmons et al. broad definition of tissue engineering is a set of
tools at the interface of the biomedical and engineering sciences that use living cells or
attract endogenous cells to assist tissue formation or regeneration, and thereby create
therapeutic or diagnostic benefit (18). In most cases, cells are seeded onto a porous,
biocompatible, and biodegradable scaffold. These constructs are allowed to grow and
develop in vitro in a bioreactor prior to implantation. The ultimate goal is for the scaffold
to gradually degrade as it is replaced by newly produced ECM as the tissue grows.
Figure 6 illustrates a flow chart of the tissue engineering paradigm.
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Figure 6 The tissue engineering paradigm is the logical progression from cell
source to an implantable replacement. The paradigm begins with a
decision into which cell source and material to use as scaffolding. The
next progression is to mature the seeded construct in vitro before
implantation. Finally, the engineered tissue is implanted in the patient
and the construct undergoes in vivo remodeling to produce a functional
replacement tissue or organ (19).
One of the first steps of engineering a tissue or organ is selecting a material to be
used as a scaffold. The biomaterials used for this application have evolved through three
generations. The first generation, beginning in the mid-20th century, of biomaterials were
industrial materials that were not developed specifically for medical use. The goal of
these materials was to be bioinert or elicit a minimal response from the host tissue. The
13

limited success of the first generation led to a development of a new generation of
biomaterials. The second generation of biomaterials were intended to elicit a nontrivial
and controlled reaction with the tissues in which they were placed to produce a desired
therapeutic advantage.

This generation also included resorbable biomaterials with

variable rates of degradation to match the requirements of the intended application. The
current or third generation of biomaterials are designed to stimulate precise reactions with
proteins and cells at the molecular level.

This generation establishes the scientific

foundation for scaffolds to be seeded in vitro and subsequently implanted in vivo (19).

Scaffold Materials
Currently, many materials are being investigated to determine their potential use
in tissue engineering. The ideal material is one that is biodegradable, bioresorbable, and
elicits a minimal foreign body response. Investigators are looking into synthetic and
biological derived polymers due to the ease of manufacturing and ability to control
material properties.

Synthetic Polymers
Polyglycolic acid (PGA), an alpha polyester, has been used since the 1970s in
reabsorbable sutures.

Hutmacher et al. reported that PGA scaffolds degrade after

approximately 8 weeks (20). However, PGA is broken down by hydrolysis, which causes
a locally acidic environment. Due to the acidic conditions, degradation of PGA can
produce a significant local inflammatory response(21).

A second type of synthetic

polymer is polylactic acid (PLA) which differs from PGA by one methyl group. PLA
14

exhibits more hydrophobic properties with less water uptake followed by a slower rate of
hydrolysis due to the additional methyl group. PLA is used in sutures, staples and
orthopedic devices. Compared to PGA, the inflammatory response to PLA is slightly less
severe and has a longer resorption time of approximately 52 weeks (22).

Biological Polymers
Polyhydroxyalkanoates (PHAs) are naturally produced polyesters that are
biosynthesized by various microorganisms. PHAs are a thermoplastic material that range
from stiff and strong to flexible and ductile depending on composition. Degradation time
of PHAs is approximately 52 weeks, as reported by Williams et al, and varies depending
on composition, molecular weight and configuration(23).

Poly-4-hydroxybutyrate

(P4HB) is much stiffer than PHA and is processed using standard polymer processing
techniques and has similar degradation times to PHAs.

Hypothesis and Objective
I hypothesize that chitosan and collagen have advantageous properties that make
them ideal for scaffolding materials in a tissue engineered heart valve.

With the

drawbacks of current aortic valve replacements, a need for an alternative that can
overcome these limitations has arisen. A possible solution to the shortcoming of current
treatment options is the production of a tissue engineered aortic heart valve. One of the
initial steps to engineering a tissue is determining the material that is biocompatible and
biodegradable. The purpose of this study is to investigate the potential of chitosan and
collagen hydrogels as scaffolding material for a tissue engineered heart valve.
15

CHAPTER II
METHODS AND MATERIALS FOR CELL CULTURE

Cell Isolation
Aortic valves were excised from freshly sacrificed pigs from a local abattoir
(Sansing Meat Service, Maben, MS). The ventricles were removed by cutting laterally
across the heart approximately half way up from the apex of the heart. The mitral valve
was revealed and a cut was then made through the opening of the valve. The lower
portion of the aortic valve was uncovered by the previous step. Once the valve was
exposed, the valve was cut between commisures of the leaflets to reveal the three leaflets
of the aortic valve. The leaflets were then removed by cutting around the cusp about one
third up the leaflet to ensure no vascular tissue would be obtained. The hearts were
rinsed in sterile phosphate buffered saline (PBS) (Sigma, St. Louis, MO) to eliminate
blood and blood clots. The excised leaflets were transported to the laboratory in ice-cold
PBS. Upon arrival at the laboratory, the leaflets were placed into a six well plate with
one leaflet per well. Leaflets were then maneuvered to lay flat on the bottom of the well.
Collagenase was made by creating a 1mg/mL solution of collagenase (Worthington,
Lakewood, NJ) and Dulbecco’s Modified Eagle Medium (DMEM) (Sigma, St. Louis,
MO). Approximately 1 mL of collagenase solution was pipetted onto the flattened
leaflets and placed in the incubator with 5% CO2 and 37ºC.
16

After 10 minutes of

incubation the ECs were removed by swabbing the leaflets with sterile swabs. These
swabs were discarded or used for EC isolation. Next, the leaflets were placed into 10mL
of collagenase solution and agitated overnight attached to a rotary bioreactor to gently
agitate the leaflets. After 12-18 hours, the collagenase/leaflet suspension was centrifuged
for 5 minutes at 1000 rpm and the supernatant was aspirated. The pellet of porcine VICs
was then resuspended in complete media (DMEM, Sigma, St. Louis, MO, 10% FBS,
Hyclone, Logan, UT, 1%Antibiotic-Antimyocyte, Sigma, St. Louis, MO) and the
previous step was repeated. The resulting pellet was then resuspended in complete media
(DMEM, 10%FBS, 1%ABAM) and plated onto a T-175 flask with 30 mL of complete
media. Cells were grown to confluence as seen in Figure 7, then used or passaged out.
Cells were maintained with standard cell culture techniques.

Figure 7 VICs grown to confluency in complete media on a T175 flask.
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Cell Freezing
VICs were frozen to obtain a storehouse of viable cells. Freezing the cells
required trypsinization of the growing cells from T-175 flask. To begin, the supernatant
was aspirated off the cells contained within the near confluent T-175 flask. Next, a wash
of approximately 10mL of PBS was performed to ensure that all complete media has
been removed.

Failure to rid the flask of media would cause trypsinization to be

ineffective and inefficient. After rinsing, the PBS was aspirated off and 7 mL of trypsin
(Sigma, St. Louis, MO) was pipetted into each flask. The flask with trypsin was then
placed in an incubator for 7-10 minutes to allow for the detachment of cells from flasks.
Extended exposure to trypsin has detrimental effects on cells. After the incubation time,
7 mL of complete media was added to each flask to inactivate the trypsin. The resulting
solution was centrifuged for 10 minutes at 1000 rpm. The supernatant was removed and
the resulting cell pellet was resuspended in complete media. A second centrifugation was
performed and supernatant removed. The resulting pellet was resuspended in complete
media so that the desired amounts of cells were in 1 mL of media per cryovial. Once in
cryovials, 10% dimethyl sulfoxide (DMSO) (Sigma, St. Louis, MO) was added to each.
The vials were immediately placed into a container partially filled with isopropenol to
control the rate of freezing in the -80ºC freezer. After 24h the vials were removed from
the isopropenol container and stored in a dry container within the -80ºC freezer.

Cell Thawing
Thawing cells required the removal of a cryovial from the -80ºC freezer. The vial
was warmed by the heat emitted by the researcher’s hand. Immediately upon thawing the
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solution was placed into 10 mL of warm complete media. This was done to dilute the
DMSO until it could be removed due to its detrimental effects on unfrozen cells. The
dilute solution was centrifuged for 10 minutes at 1000 rpm.

The supernatant was

removed and the cell pellet was resuspended in the appropriate amount of complete
media. The suspension was then plated onto desired flask and cultured as normal. Media
was changed after 24 hours to eliminate cells that did not survive the thawing process.
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CHAPTER III
EVALUATION OF CHITOSAN AS A BIOMATERIAL FOR TISSUE ENGINEERING

Introduction
Chitosan is an abundant biopolymer that is derived from shellfish, such as crab and
shrimp. This biopolymer is considered industrial waste by the seafood industry which
allows for an ample supply. Chitosan is formed when the number of N-glucosamine
units is higher than 50%. When the amount of N-acetyl-glucosamine units is higher than
50% the molecule is known as chitin. Figure 8 depicts the molecular structure of chitin
and chitosan. Chitosan, a linear polysaccharide, has been researched more than chitin
due to its ability to be readily solubilized in dilute acid solutions. Source and preparation
method dictate the molecular weight, which typically ranges from 300kD to 1000kD. In
addition, commercially available chitosan has a degree of deacetylation of 50 to 90%.
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Figure 8 Molecular structure of chitin, a biopolymer from the exoskeletons of
crustaceans, and chitosan, a readily solubilized, biocompatible
biopolymer.
Chitosan shows great promise as a material for biomedical applications, including
drug delivery, wound healing, and tissue engineering. The interest in chitosan is due to
its excellent biocompatibility, biodegradation, and anti-inflammatory properties.
Tomihata and Ikada studied the biocompatibility of chitosan in vitro and in vivo in rats
(24). Their study demonstrated how the rate of degradation affected the biocompatibility
of chitosan scaffolds.

The study also revealed that as the degree of deacetylation

increases, the rate of degradation decreases. This slower degradation rate did not elicit an
inflammatory response as severe as the lower deacetylated (faster degrading) samples.
The faster degradation causes an accumulation of degradation particles at the implant
site, thus causing a more severe inflammatory response.
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Chitosan is broken down into amino-sugars, which are excreted or incorporated
into GAG or glycoprotein metabolic pathways (25). The body degrades chitin and its
derivatives through enzymatic hydrolysis mediated by chitinase and lysozymes contained
within macrophages (26). In addition, hydrolases can also breakdown chitin depending
on the degree of deacetylation.
As of October 2008, a simple PubMed search of chitosan receives 5,234 hits,
which demonstrates the interest in this biopolymer. While most research revolves around
using chitosan in a drug delivery form, chitosan shows promise in many areas of tissue
engineering. Jiankang et al. evaluated chitosan-gelatin hybrid scaffolds in hepatic tissue
engineering (27). Nettles et al. explored chitosan as a potential material used for tissue
engineering cartilage (28). Oliveira et al. studied the engineering of endochondral bone
utilizing chitosan based scaffolds (29). Whereas, Blan et al. examined the possibility of
using chitosan as a biomaterial to support the formation of contractile 3D heart muscle
(30). Chitosan has also received some attention as a potential heart valve scaffold
material (31).

Hypothesis and Objective
I hypothesize chitosan will possess strength similar to native decelluarized leaflets
and cells will attach throughout the scaffold. The objective of this study is to evaluate
chitosan as a material for a tissue engineered heart valve. The physical properties of
chitosan scaffolds will be investigated to gain insight into the structure and performance
of these scaffolds. Additionally, scaffolds will be produced and studied to determine if
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scaffolds made from chitosan can support the attachment and growth of porcine aortic
valve interstitial cells.

Methods and Materials
Chitosan (low molecular weight) (Sigma, St. Louis, MO) was dissolved (1%w/v)
in Glacial Acetic Acid (Sigma, St. Louis, MO). The solution was stirred for 4-6 hours to
ensure that chitosan was fully dissolved. The chitosan was then poured 1 mL per well
into a 24 well plate. Next, the plate was placed into a -80ºC freezer for at least 24 hours.
The samples were frozen at -80ºC rather than -20ºC, due to the effects of freezing rate on
pore size and distribution (32). The freezing rate regulates the crystallization of water
within the solution, thus, the size of the crystals dictate the pore size made upon
lyophilization (32). Once frozen, the samples were lyophilized on a Flexi Dry (FTS
Systems Inc., Stone Ridge, NY) for 24 hours. The scaffolds were rehydrated in a graded
series of ethanol from 100 to 70%. At each step, the scaffolds were covered with enough
of the appropriate ethanol to cover the samples and allowed to sit for approximately 30
minutes. Samples were cut into 5 X 10mm strips and remained in 70% ethanol for 2-6
hours to sterilize. Following sterilization, samples were rinsed twice in PBS.

Scaffold Preparation
Scaffolds were sterilized in 70% ethanol and then rinsed twice with sterile PBS to
remove any residual ethanol. After rinsing with PBS, a 30 minute rinse in sodium
hydroxide (0.1M NaOH) was conducted. This was performed to stabilize the scaffolds
and create favorable environment for cells to attach. After removing the scaffolds from
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NaOH, 3 mL of complete media was added to each scaffold and placed into an incubator
30 minutes prior to seeding.

Seeding Method
Three different methods for seeding were tried. The first method was blotting the
scaffold dry before pipetting the cell suspension onto the scaffold. The scaffolds were
allowed to sit undisturbed for 1 hour then 3 mL of complete media was added to each
scaffold.

A second method for seeding employed was an agitation method.

This

involved pipetting the cell suspension onto the scaffold and placing on a Belly Dancer
Shaker (Stovall Life Sciences, Greensboro, NC) within an incubator. The third method
of seeding was injecting cells into the scaffolds via a 20 gauge syringe and then placing
into an incubator. One hour later 3 mL of complete media was added to each scaffold.
The number of cells seeded onto scaffolds was 1, 3, or 5 million.

Scanning Electron Microscopy
Pore size was visualized and measured using scanning electron microscopy
(SEM).

Samples for SEM were fixed in 12.5%glutaraldehyde in 0.1M sodium

cacodylate buffer. The samples were then rinsed in phosphate buffer, and post fixed with
2% Osmium tetraoxide in 0.1M phosphate buffer. Next, samples were dehydrated in a
graded series of ethanol beginning at 50% ethanol and increasing by 25% each series.
Each series lasted approximately 30 minutes. Samples were chemically dried using
hexamethyldisilazane (HMDS) before air drying overnight. The dried samples were
mounted on aluminum stubs, coated with gold/palladium, and viewed on a JEOL JSM24

6500F scanning electron microscope at 5kV. Images were taken at 300X and were
exported with scale bars. Images were then analyzed in ImageJ (NIH) imaging software
to determine an average pore size and distribution of pores. Pore size was measured by
setting the scale with in ImageJ then overlaying lines on top of pores in the SEM image.
In order to determine the average pore size a 20,000 µm2 area was sectioned of by
overlaying a rectangle on top of the image.

Then pores within the quadrant were

measured and averaged to give the average pore size.

Hematoxylin and Eosin Staining
To determine cell distribution and content, samples were stained with
Hematoxylin and Eosin (H&E). Samples were first fixed in 10% buffered formalin for 1
hour then placed in PBS until staining. Samples were imbedded in paraffin and sectioned
at a thickness of 10µm. The sections were then mounted to glass slides and prepared for
staining.

Staining began with submersion of slides in Clear-Rite 3 followed by

submersion in a series of alcohol dilutions at 100, 95, and 70%, respectfully. Slides were
rinsed by submersion in distilled water. Hematoxylin staining was then performed via
submersion followed by a rinse in distilled water. Hematoxylin stained the nucleus blue.
Next, the slides were submerged in 3% Glacial Acetic Acid and rinsed once again in
distilled water. Submersion in a Bluing Solution was performed followed by a rinse in
distilled water. The slides were then rinsed in 70% alcohol and then stained with Eosin Y
solution. Eosin stained chitosan and collagen bright red. A rinse in 95% alcohol and
absolute alcohol was performed. Slides were then submerged in Clear-Rite 3 twice.
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Finally, cover-slips were applied using 1-2 drops of mounting medium. Slides were
viewed by a light transmission microscope at 10X and 20X.

Laser Scanning Confocal Microscopy
Laser scanning confocal microscopy (LSCM) was performed by staining the
scaffolds with 5µM calcein-AM and 5µM ethidium homodimer, which reveal live or
dead cells, respectively. The stains were left on the scaffolds for approximately 15
minutes then rinsed in PBS. The scaffolds were then viewed on a Zeiss LSM 510
confocal microscope. The scaffolds were stained 24 hours after seeding to determine cell
viability and number.

Dissolution Test
Degradation by hydrolysis was measured over an 8 week period. The rate and
mode of degradation depends on the material deacetylation and crystallinity. Chitosan
scaffolds with greater than 80% deacetylation and/or high crystallinity exhibit little
degradation.

To estimate the stability of chitosan scaffolds, a dissolution test was

performed. These tests were performed by placing 6 scaffolds into a 50 mL tube, one
scaffold per tube. Then 50 mL of media was added to the tube with either complete
media or media without FBS and incubated. Over 8 weeks, the media was changed
weekly and 10 mL was used to measure the kinematic viscosity. Samples incubated in
the absence of FBS provided data on the degradation by hydrolysis, while tests performed
in the presence of FBS provided information on the degradation by hydrolysis and serum
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proteins/enzymes. The viscosity was measured using a capillary viscometer placed into a
water bath regulated to 37ºC with an increase in viscosity indicating material degradation.
The capillary viscometer was loaded with the appropriate form of media and
allowed to equilibrate to the temperature of the previously mentioned water bath. While
placing a finger over the vent, the media was drawn up through the capillary past both
indicator lines. The vacuum was then removed with a finger still over the vent. The
finger was then removed and the efflux time for the fluid to flow downward from the top
indicator line to the bottom indicator line was recorded. This process was performed 3
times per scaffold. To obtain the kinematic viscosity the recorded time was placed into
the following equation:

Kinematic Viscosity = (Viscometer constant X Efflux time)

(Eq. 1)

The viscometer constant was a known value that is derived by running a known substance
through the viscometer. This value is typically provided by the manufacture. The
kinematic viscosity of each scaffold was then averaged and plotted each week over an
eight week period.

Chitosan Scaffold Tensile Testing
The tensile strength of the scaffolds was also evaluated by using the MACH1
micromechanical testing system as seen in Figure 9. Before tests were run, the 1kg load
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cell was calibrated. The samples were placed into grips, which consisted of two steel
plates held together by two nuts as seen in Figure 10. The testing sequence began by
zeroing load cell and position to create a reference point. Next, the protocol called for a
simple displacement, which was ran until failure of the scaffolds occurred.

Figure 9 MACH1 micromechanical testing system used to evaluate the tensile
strength of chitosan scaffolds.

28

Figure 10: Clamps used to hold scaffolds while tensile test were perform. Two
bolts drew the metal pieces together to clamp the scaffolds

Results
The chitosan scaffolds were analyzed under SEM to determine pore size. The
scaffolds appeared to have uniform distribution of pores.
sufficient pore size to accommodate VICs.

Also, the scaffolds had

The ideal pore size is deemed to be

approximately 15 µm, which is a few microns larger than an average interstitial cell to
allow for mass transport of nutrients and byproducts. SEM pictures confirm that pores
were large enough for VICs to infiltrate and attach as seen in Figure 11, and pore
diameter was measured. The average pore size was determined to be 18.76±7.75 µm.
Further inspection of SEM pictures revealed fairly uniform distribution of pores.
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Figure 11 SEM image of chitosan scaffold, which reveals a favorable pore size
and distribution.
H&E staining was conducted to determine the number of cells retained or
attached to the scaffold and distribution of cells throughout the scaffold. H&E stained
constructs can be seen in Figure 12 and13. H&E staining revealed ample pore space
throughout the scaffolds. More cells were seen in scaffolds with a higher seeding density
at various depths throughout the samples. However, the staining revealed extremely low
cell counts overall, even from higher seeding densities.
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Figure 12 A section of a chitosan scaffold stained with H&E. The chitosan is
stained red, and reveals ample pore distribution.
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Figure 13 Section of chitosan stained with H&E after 72 hours. Chitosan is
stained red and cells blue, and displays the cell distribution and
infiltration into the scaffold. The scaffold was seeded via the agitation
method with 3 million cells.
Confocal microscopy was performed on samples to determine cell number and
viability. The Live/Dead staining of the scaffolds revealed that most of the cells seeded
were dead within 24 hours. However, images obtained did show high cell retention or
cell numbers. An example image of the Live/Dead staining of chitosan scaffolds can be
seen in Figure 14.
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Figure 14 LSCM images of chitosan scaffolds prepared traditionally (A,B) and
NaOH rinsed method(C,D). Live cells were stained with calcein-AM,
which fluoresce green, while dead cells and autofluorescent chitosan
are depicted in red. Images were taken 24 hours after seeding via
injection. Scale bars represent 100 µm.
Chitosan autofluoresces red as seen above, and dead cells are stained red by eithidium
homodimer. The numerous red dots or dead cells show good values of cells were seeded
into the region. Also the new method of rinsing scaffolds in NaOH did result in a small
amount of live cells, but the method still needs to be optimized to efficiently seed the
scaffolds.
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An average ultimate tensile strength of 0.0455±0.006 MPa over 6 samples was
revealed from tensile testing. In addition, testing found an average elastic modulus of
0.1081±0.016 MPa. Table 2 shows the strength breakdown of the 6 matrices and Figure
15 is the stress versus strain curves.

Table 2 Table of strengths of 6 chitosan scaffolds measured via the MACH1
Scaffold
Scaffold A
Scaffold B
Scaffold C
Scaffold D
Scaffold E
Scaffold F
Average

UTS (MPa)
0.041086651
0.056835734
0.046987665
0.044920079
0.043272502
0.040496483
0.0455 ± 0.006

Elastic Modulus (MPa)
0.0846
0.122
0.099
0.113
0.128
0.102
0.1081 ± 0.016

Stress vs. Strain
0.06

Stress (MPa)

0.05
0.04
0.03
0.02
0.01
0
0

0.2

0.4

0.6

0.8

1

Strain
Scaffold A

Scaffold B

Scaffold C

Scaffold D

Scaffold E

Scaffold F

Figure 15 Stress vs. strain curves used to determine UTS and elastic moduli.
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The eight week dissolution tests revealed that little to no degradation occurred.
Visual inspection of scaffolds each week showed no evidence of degradation. The
viscosity of the media with and without FBS showed no change throughout the eight
week period. The lack of change of the viscosities of scaffolds in media without serum
indicated that little degradation occurred through hydrolysis. In addition the minimal
change of viscosities of scaffolds in media with FBS suggested no degradation of the
scaffolds by serum proteins/enzymes. The viscosities over the eight weeks can be seen in
Figures 16 and 17.
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Figure 16 Change in viscosity of media with FBS over eight weeks
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Scaffold F
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Figure 17 Change in viscosity of media without FBS over eight weeks

Discussion
While chitosan scaffolds are easily produced, there exists a large variation
between scaffolds from batch to batch. Not only were variations seen from batch to
batch, but also between wells as seen in the Figure 18, where image A shows pores with a
different morphology/topography than image B. These variations possibly arrive due to
impurities within the chitosan, or variations of external environmental conditions, such as
relative humidity, temperature disparities, etc, when preparing the scaffolds.
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A

B

Figure 18 SEM images of chitosan scaffolds taken at 5kV on JOEL SEM , which
show different morpholgoy/topography between samples. Image A
shows a more random order of pores compared to the more uniformed
pores in image B.
Difficulties arose when imaging due to the charge build up of the scaffolds, which
causes the images to be distorted and less sharp. This could be overcome by a longer
period of sputter-coating; however, lowering the voltage in which the image is taken can
also allow for images to be taken at a lower quality. Also handling the scaffolds during
preparation for SEM can damage the structure of the samples, which necessitates care
when processing the samples. The pore size was found to be suitable for cell infiltration
and mass transport. Also, pore distribution appeared uniform throughout the samples.
The method by which the scaffolds were created is widely accepted. The process
of rehydration of scaffolds varies among researchers. Some researchers choose to change
the ethanol concentration by 10% per series, while other use a 5% step. In addition, some
groups choose to rinse the scaffolds in NaOH after rehydration. Each of these methods
was explored with limited success. No difference could be discerned from the variation
between size of steps in the previously mentioned ethanol series.
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However, when

chitosan was dissolved in 0.1M acetic acid live cells were seen attached on top of dead
cells. The rinsing of scaffolds had the most promising results as seen in Figure 14.
LSCM was found to be a very useful tool in determining the overall outcome of
seeding scaffolds. In addition, the autofluorescence of chitosan made viewing the pore
size and distribution easy. Overall the number of cells attached was promising; however,
lack of viable cells after 24 hours was a major concern. Once it was determined that the
traditional method of scaffold preparation killed the seeded cells via a nonfavorable pH
environment that was an artifact of the rehydration process, variations to the method were
made. To eliminate the effects of ethanol on the scaffolds, the time spent at each interval
in ethanol and number of PBS rinses before seeding was varied. This proved to only
minimally improve the outcome of seeding. To aid in cell attachment, scaffolds were
incubated in complete media prior to seeding, which gave serum proteins the opportunity
to penetrate within the scaffold to aid in cell attachment. Each of these changes yielded a
minimal amount of positive results. The only cells that were found viable were attached
on top of another cell. This leads to the conclusion that the chitosan matrix was killing
the cells. A new batch of chitosan solution was made from a higher grade chitosan. In
addition, chitosan was dissolved in weaker acetic acid. None of these changes affected
the fate of the cells. It was then suggested to rinse the scaffolds in 0.1M NaOH to
stabilize the constructs and combat any residual pH issues from rehydration.

This

showed the most promising of the changes to the traditional method. As seen in Figure
14 cells seeded onto scaffolds that were rinsed in NaOH were viable after 12 hours. The
results from a rinse in NaOH offer hope that further optimization of the seeding method
and cell quantity can be made.
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The mechanical data showed that scaffolds from the same batch had the same
mechanical properties.

The strength of chitosan scaffolds when compared to

decelluarized and native valves is considerable lower (33). This means that the goal of
creating a tissue that has the strength of native tissues is not met. Also the lack of
strength suggests that a chitosan scaffold would not perform well under physiological
loading.
The dissolution test revealed scaffolds do not degrade over a period of 8 weeks.
Both scaffolds in media with or without FBS showed no signs of degradation. Since the
viscosity of the media that was removed each week remained constant, it can be
concluded that the majority of degradation is performed by enzymes within the body.
Degradation of scaffolds by hydrolysis or serum protein/enzymes does not have an
apparent effect on the overall degradation.
Current literature suggests chitosan appears to have a lot of potential as a
biomaterial for tissue engineering constructs.

The biocompatibility and favorable

degradation of chitosan makes it an interesting material to research for biomedial
applications. However, the variation between batches and detrimental effects on VICs
causes one to reassess the use of chitosan for this application.

Conclusion
Chitosan, as expected, was easily processed and made into scaffolds. The study
revealed good pore size and distribution throughout the scaffolds.

Also, a cell

distribution throughout the scaffolds was shown in H&E staining. However, cell viability
was a major drawback of using traditional methods for processing chitosan scaffolds.
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Live/Dead staining displayed large quantities of dead cells. A NaOH rinse of rehydrated
scaffolds increased the number of viable cells; however, further optimization is needed of
the processing of chitosan scaffolds.

Future Studies
Further research is needed to evaluate chitosan as a biomaterial used in
scaffolding. Since ECs have been successfully seeded onto chitosan matrices before (31),
ECs should be tried on the chitosan scaffolds to determine the cause of death of the cells.
If the processing of the scaffolds is incorrect then this reseeding would result in dead
ECs. Supplementing scaffolds with collagen or gelatin should also be investigated to
determine if their presence increases the cells ability to attach. Wang et al. investigated a
mixture of chitosan and collagen in periodontal cartilage tissue engineering with
promising results (34). In addition, to increase strength of the scaffolds, genipin should
be investigated as a possible cross-linking agent(35). This would allow for a stronger
framework for the cells to attach and proliferate.
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CHAPTER IV
EVALUATION OF COLLAGEN AS A TISSUE ENGINEERED
SCAFFFOLD MATERIAL

Introduction
Relative to traditional methods of tissue engineering heart valves, a less traveled
avenue is the method in which cells are entrapped in a gel.

This form of tissue

engineering relies on the established knowledge that cells embedded in collagen gels
contract and compact the gels.

The resulting compaction and contraction in turn

increases the density of the collagen many folds (36). The process first involves mixing
soluble, fibrillar collagen with the desired cell type. Once the collagen-cell mixture is
neutralized, soluble collagen reassembles into fibrils and thus a gel is made. The desired
cells within the gels begin to interact with the collagen fibrils and contract the gel. In
vitro contraction shows similarities to wound healing in vivo (37). This method of tissue
engineering is currently being applied in fabrication of blood vessels, mitral valve
chordae and the development of heart valve leaflets in early stages.
Tissues of the body are in complex environments that can subject a tissue to
various mechanical and biochemical factors that regulate the function of cells. The
endocrine, autocrine and paracrine pathways along with ECM contacts send signals to
cells under normal and pathological conditions. Thus to engineer a tissue ready for
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implantation, the specimen must be pre-conditioned. This is done in vitro by subjecting
the sample to biochemical factors and mechanical stimuli that are present in vivo.

Transforming growth factor- β1 (TGF-β1)
TGF-β1 is a profibrotic cytokine that stimulates the production of ECM proteins
in a number of different organ systems. This growth factor is secreted by a variety of cell
types including vascular endothelial and smooth muscle cells with practically all cells
having TGF-β1 receptors. Since TGF-β1 is secreted in an active form, it must be cleaved
via the action of proteolytic enzymes, cell-cell interaction and acidification (38). It has
also been seen to contribute to the increase of cell hypertrophy, polyploidy, and
hypertension (39).

Cipollone et al. reported that TGF-β1 may be important in the

stabilization of atherosclerotic plaques through the inhibition of local inflammation (40).
However, an over expression of TGF-β1 can lead to an excess amount of ECM protein
production characteristic of fibrosis. In a tissue engineering setting, TGF-β1 is known to
vary cell proliferation and compaction of collagen gel constructs (41;42).

Platelet derived growth factor (PDGF)
The role of PDGF in soft tissues and bones has not been well established, but is
known to be the first growth factor to initiate most wound healing. The growth factor
attaches to transmembrane receptors on target cells when activated. PDGF is secreted by
ECs, smooth muscle cells, and activated macrophages. It promotes smooth muscle cell
migration, proliferation and matrix production associated with intimal thickening in
arteriosclerosis. . The main function of PDGF is stimulating cellular replication. For this
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reason, Stegemann et al. studied the effect of PDGF on collagen gels used in tissue
engineering (41;42).

Matrix Metalloproteases
The purpose of pre-conditioning an engineered specimen is to initiate remodeling
of ECM and degradation of the scaffold.

Matrix Metalloproteases are proteolytic

enzymes able to degrade various ECM proteins such as collagen, laminin, and
fibronectin. Some MMPs are known to be collagenases, which cleave proteins at a small
number of sites. This allows structural integrity of the matrix to be retained, while
enabling cell migration. Other MMPs are less specific and are able to act where needed.
This type of less specific MMP is vital to allow cells to divide when embedded in matrix.
The activity of MMPs are rigorously controlled by mechanisms including local
activation, confinement by cell-surface receptors, and secretion of inhibitors.

Hypothesis and Objective
I hypothesize that regular media in cyclic pressure will show the least amount of
compaction with the highest ultimate tensile strength, TGF-β1 will effect compaction and
expression of MMPs, and PDGF will show minimal effects on remodeling potential. The
objective of this study was to determine the optimal conditions required by collagen gels
to produce a tissue engineered aortic heart valve. The affect of supplementing growth
medium with TGF-β1 or PDGF-BB and the addition of cyclic pressure was evaluated,
with regard to remodeling potential.
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Methods and Materials
Hydrogels were made using porcine aortic VICs. A suspension of 106 cells was
made in 3X DMEM, 10% FBS, 2 mg/mL concentration of Type I collagen (BD Sciences,
Franklin Lakes, NJ), and the appropriate amount of 0.1M NaOH to neutralize the solution
(pH 7.0). Using a 12-well plate, approximately 1.25 mL of the solution was placed in
each well and incubated at 37ºC for 1 hour. After one hour or once the gels had begun to
solidify into a gelatinous state, the gels were immersed in 3 mL of complete media. The
gels were allowed to sit undisturbed for 24 hours and were then liberated from the wells
using a sterile scalpel. Gels were allowed to compact for 7 days, and were exposed to
complete growth media, TGF-β1 (human, Sigma, St. Louis, MO) supplemented and
PDGF-BB (rat, Sigma, St. Louis, MO) supplemented complete media. The desired
concentration of TGF-β1 and PDGF-BB supplemented media was 2 and 5 ng/mL,
respectively. These growth factors were reconstituted in 4mM HCl with 0.1% bovine
serum albumin.

Test Conditions
Two different growth conditions were used to test the effects of cyclic pressure on
the collagen gels. Static conditions were tested with the 12 well plates placed in an
incubator at 37ºC and 5% CO2 and the appropriate media being changed every 48 hours.
A pressurized condition was also tested utilizing a pressure chamber within an incubator.
The pressure chamber as seen in Figure 19 was made from acrylic. Two solenoid valves
were used as exhaust and input. The input valve was connected to compressed air via a
pressure regulator, and the exhaust was expelled into the incubator. The solenoid valves
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were controlled via a LABView program in which the input valve would be activated for
0.6 seconds and the exhaust for 0.4 seconds. The input time was designed to mimic the
aortic valve being closed during diastole, thereby increasing the pressure within the
chamber. The exhaust time was based upon the drop of pressure experienced by the
aortic valve when it is opened during systole. The valves were programmed to cycle at 1
Hz, which correlates to a heart rate of 60 beats per minute. A pressure transducer was
used to convert pressure to a digital signal that was monitored by a LabVIEW program.
The pressure range in which the gels were tested was 60-80 mmHg. Samples were
placed in the pressure chamber for 7 days with the appropriate media being changed
every 48 hours.

Figure 19 Pressure chamber used to expose gels to cyclic pressure over a 7 day
period.
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Compaction
Compaction was measured every two days using digital calipers and digital
images. Using digital calipers, the disc were allowed to remain in complete media and
measured being careful not to come in contact with the gel or media. In addition, digital
images of the gels were taken with a ruler placed beside the 12 well plate. These images
were imported into ImageJ (NIH) where a global scale was set by placing a line of a
known pixel amount over the known length of the ruler. ImageJ was able to calculate the
length of lines drawn over the diameter of the discs. Both methods of measurement were
used every 2 days.

Gel Tensile Testing
After 7 days, the samples were removed from their respective conditions and a
tensile strength test performed. Samples were cut into uniform 3.5mm strips and alligator
clips were made to integrate into the MACH1 micromechanical testing system. For
testing of the gels, a 1kg load cell was used. To test the samples, the load cell was first
calibrated and then alligator clips were mounted. The samples were placed into the
alligator clips as seen in Figure 20, care was taken to ensure an adequate amount of
sample was clamped. The length between clamps was measured with digital calipers and
recorded. The load cell and actuator position was zeroed. Cyclic tensioning at 1Hz was
then performed to precondition the samples. A simple displacement of 100µm/s was
conducted to pull the gels to failure. Load and position was recorded every tenth of a
second and saved into a text file. Data analysis determined ultimate tensile strength and
elastic moduli using Microsoft Excel.
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Figure 20 Alligator clips used to clamp collagen gels into MACH1 system to
determine ultimate tensile strength

RNA isolation
RNA isolation was performed using an RNeasy kit from (Qiagen, Valencia, CA)
according to the manufacturer’s instructions. Briefly, gels were place into a 3mL tube
and 300 µl of RLT Buffer was added. The gels were immediately homogenized until
uniform. Next, 590 µl of double-distilled water and 10 µl of Proteinase K (20mg/mL in
water, Promega, Madison, WI) were added to the homogenate. The tubes were then
placed in a water bath at 55ºC for 10 minutes to activate Proteinase K. The supernatant
was pipetted off and place into a microcentrifuge tube. To the supernatant, 0.5 volumes
of 100% ethanol was added and mixed by pipetting.

700 µl of the samples were

transferred into RNeasy mini columns in 2 mL collection tubes and centrifuged for 15
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seconds at 10,000g. The liquid that passed through the columns was discarded. The
columns were then filled with 700 µl of RW1 and centrifuged at 10,000g for 15 seconds.
After centrifugation, the collection tubes were replaced and 500 µl of RPE was added to
each column. The columns were then centrifuged for 15 seconds and the flow through
was discarded. Another 500 µl of RPE was added to each column and centrifuged for 2
minutes. The flow through was discarded and the empty column was then centrifuged for
1 minute. The columns were then removed and placed into microcentrifuge tubes. Next,
50 µl of RNase-free water was added to each column and centrifuged for 1 minute. The
RNeasy spin columns were then discarded and the tubes containing RNA were stored at 80ºC. The quality of isolated RNA isolated was assessed using a NanoDrop 1000
UV/Vis Spectrophometer. 1.5µl of isolated RNA was loaded onto the reading stage and
samples were read. Levels were read at 260/280 with quality RNA deemed to have a
ratio between 1.8-2.0. Also levels were also checked at 230 to assess the purity of RNA
with values approximately 1.8 being pure RNA.

Quantitative Real Time Polymerase Chain Reaction
Quantitative RT-PCR was performed to measure the relative change in mRNA
expression of genes MMP-1 and MMP-3, as previously reported(43). RT-PCR was
carried out using the iScript One-Step RT-PCR kit with SYBR Green (Bio-Rad,
Hercules, CA). A master mix was created using 0.25 µl SYBR Green One-Step Enzyme
Mix, 6.25 µl 2X SYBR Green Reaction Mix, 0.25 µl of forward and reverse primers,
seen in Table 3, and RNase/DNase-free distilled water to give a final volume of 11.5 µl
per sample. The master mix was pippetted into a 96-well plate, and 1 µl of total RNA for
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each sample was added, yielding a final reaction volume of 12.5 µl. cDNA synthesis and
PCR amplification was performed using the following steps: 50ºC for 30 min; the
reaction mixture was then heated to 95ºC for 5 min; a 60 cycle two-step PCR was then
performed consisting of 95ºC for 15 seconds followed by 1 min at the annealing
temperature, 55ºC. Reactions were carried out utilizing an i-Cycler Thermal Cycler (BioRad, Hercules, CA).

Table 3 Primers for qRT-PCR to determine relative expression of MMP-1 and
MMP-3
Gene Symbol
MMP-3 Left
MMP-3 Right
MMP-1 Left
MMP-1 Right
18S Antisense
18S Sense

Primer Sequence 5'-3'
TGTGGAGTTCCTGATGTTGG
GGCTGAAGTCTCCGTGTTCT
TTTCCTGGGATTGGCAAC
TCCTGCAGTTGAACCAGCTA
CGGGTCGGGAGTGGGTAAT
CGGAGAGGGAGCCTGAGAAA

Statistical and Data Analysis
Results of compaction data was processed in Microsoft Excel.

Conclusions

regarding gel compaction were made based off of paired t-test with a p-value <0.01
significant (n=12).

Mechanical testing data was calculated using Microsoft Excel.

Changes in UTS and elastic moduli were assessed for significance through paired t-test
with p-values <0.1 considered significant (n=3). Also relative gene expression was
calculated using Microsoft Excel. Experiments were run for each condition, and RNA
was pooled from four samples. Relative expression was calculated assuming a 100%
PCR efficiency using 2(ΔCT) where CT is the cycle threshold for the gene, and ΔCT is the
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difference between the house keeping gene, 18s, and the experimental groups. Means
and paired t-test were calculated with significance determined based on a p <0.05.

Results
Compaction of the scaffolds was recorded every other day over a 7 day period.
The average diameter of the collagen gels is seen in Table 4. Statistical analysis was
performed in Microsoft Excel and can be found in Figures 21, 22, and 23. Significant
compaction was found throughout all treatment groups for the time period between Day 0
and Day 2 (p-value < 0.01). Gels subject to pressure in PDGF supplemented media
showed the only significant compaction from Day 2 to Day 4. There was also significant
compaction of all gels subjected to pressure from Day 4 to Day 6. However, only the
PDGF supplemented samples in static conditions had a significant change in compaction
over the same time period.

Table 4 Relative percent compaction over 7 days to determine the compaction of
gels.

Regular static
Regular pressure
TGF static
TGF pressure
PDGF static
PDGF pressure

Day 2
50.9±0.02
68.6±0.06
36.9±0.03
71.1±0.07
39.6±0.03
65.1±0.03
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Day 4
47.8±0.04
66.5±0.04
38±0.04
69.9±0.07
39.2±0.02
57.8±0.03

Day 6
50±0.03
57.4±0.03
34.8±0.02
64.2±.09
42.9±0.02
52.6±0.02
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Day 2

Day 4

Day 6

Figure 21 Gel compaction of collagen gels over 7 days in regular media and
subjected to either static or cyclic pressure.

Gel Compaction TGF Supplemented
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Figure 22 Gel compaction of gels in TGF supplemented media subjected to
either static or cyclic pressure over 7 days.
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Figure 23 Compaction of collagen gels in PDGF supplemented media subjected
to either static or cyclic pressure over 7 days.
The ultimate tensile strength and elastic modulus was measured for each
treatment after 7 days. There was a statistically significant decrease in ultimate tensile
strength in all treatments. In addition, only PDGF saw a significant decrease in the
elastic modulus. The ultimate tensile strength comparison is shown in Figures 24, 25 and
26. Elastic moduli are compared between treatments in Figures 27, 28 and 29.
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Figure 24 Graph comparing the ultimate tensile strength of collagen gels in
regular media.
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Figure 25 Graph comparing the ultimate tensile strength of collagen gels in TGF
supplemented media.
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Figure 26 Graph comparing ultimate tensile strength of collagen gels in PDGF
supplemented media.
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Figure 27 Graph comparing the elastic modulus of collagen gels in regular
media.

54

Elastic Modulus TGF Supplemented
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Figure 28 Graph comparing the elastic modulus of collagen gels in TGF
supplemented media.
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Figure 29 Graph comparing the elastic modulus of collagen gels in PDGF
supplemented media.
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Gene expression of MMP-1 and MMP-3 was measured using quantitative real
time PCR. qRT-PCR data showed no measureable relative expression of MMP-1 or
MMP-3 under static conditions over all treatments. MMP-1 and MMP-3 expression was
evident in both regular and PDGF supplemented media, yet they showed no significant
difference in expression. However, a 27.17 fold increase in MMP-1 and a 924 fold
increase in MMP-3 relative gene expression was observed in samples supplemented with
TGF under cyclic pressure. Gene expression data is shown in Figures 30 and 31.

Relative Gene Expression

35
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MMP1 Gene Expression
*

Regular Pressure
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TGF Pressure
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PDGF Pressure

15
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0
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Figure 30 Graph of relative gene expression to determine the expression of
MMP-1 in gels subjected to cyclic pressure.
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Figure 31 Graph of relative gene expression of MMP-3 in collagen gels exposed
to cyclic pressure

Discussion
A thorough analysis of collagen gels as a potential scaffold for a tissue engineered
heart valve was performed via seeding with valvular interstitial cells. Significant gel
compaction was found from Day 0 to Day 2 throughout all treatment groups. This
suggests there was instantaneous compaction activity of VICs regardless of pressure
environment or media type. A differential time response was evident between groups at
later time points. Gels subject to pressure in PDGF supplemented media showed the only
significant compaction from Day 2 to Day 4. There was also significant compaction of
all gels subjected to pressure from Day 4 to Day 6. This implies that application of cyclic
pressure sustains VIC collagen compacting activity. PDGF appears to show more
regulatory implications on compaction than TGF or normal growth media. This is further
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evident due to the PDGF supplemented samples in static conditions from Day 4 to 6 had
the only significant increase in gel diameter, thus decreasing compaction.
Digital imaging was the preferred method for obtaining compaction data. This
method eliminated possible contamination by contacting the scaffold or media with the
calipers. Also, images allowed for more precise measurement of the gel diameter. When
using calipers, difficulty arose when gels would be in an awkward position and calipers
could not align with the major axis of the collagen gels. Imaging allowed for a near
instant diameter reading, minimizing the length of time the gels would be outside an
incubator.
Mechanical properties were characterized to investigate the effects of the sample
treatments on the structural integrity of the gels. A significant decrease in ultimate tensile
strength was observed in all treatments subjected to cyclic pressure. In addition, only
PDGF samples under pressure saw a significant decrease in the elastic modulus. This
was possibly an artifact of a small sample size and large deviation.
Difficulties arose in the tensile testing of the gels. The diameter of the gels after 7
days is approximately 10 mm, rendering sample handling awkward and difficult. In
addition, the clamps used for testing of chitosan scaffolds could not be employed due to
the damage the clamps were causing to the gels and the size of collagen gel samples.
Sample sizes were small, which necessitated the use of alligator clips, so clamping the
appropriate amount of sample was tedious. Due to the elasticity of samples, tensioning to
failure was problem. Often the samples would neck down but would not completely fail.
The lack of a specific failure threshold and slippage resulted in disproportionate variance.
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Real Time PCR was run to determine the amount of relative expression of MMP1 and MMP-3. When a heart valve is actively remodeling, both MMPs are expressed.
MMP-1 was investigated to determine the direct impact on collagen in the gels. The
results of RT-PCR revealed that neither MMP-1 nor MMP-3 was expressed in static
culture. This indicates that the constructs are not actively remodeling in static culture.
However, the gels under pressure do not expel as much water content or contract as much
as static gels, possibly to dampen the load experienced by gels under pressure. Under
pressure, gels are actively remodeling, which is seen by the expression of both MMP-1
and MMP-3.

A possible reason for the decrease in UTS is MMP-1, which is an

interstitial collagenase that breaks down type I, II and III collagens, is expressed in
samples subjected to cyclic pressure. MMP-3 was looked at to see general remodeling
activity not directly influenced by type I rat tail collagen initially in the gels. MMP-3
was seen to be expressed even more than MMP-1, revealing that gels were actively
remodeling the ECM. This activity, in addition to the effects of MMP-1, reduces the
strength of gels when exposed to cyclic pressure.
Stegemann et al. investigated the effects of PDGF on vascular smooth muscle
cells in collagen gels(42). They reported that when gels were mechanically stimulated by
stretching and supplemented with PDGF, compaction was reduced. Interestingly, when
VICs are exposed to similar conditions, as in the current study, compaction of collagen
gels was reduced when exposed to PDGF and pressure. Stegemann postulated that
reduced compaction was a result of MMPs being over-expressed, which is confirmed by
the results of this study.
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The lack of compaction raises an interesting question as to the impact on the gel
as a whole. Since there is less compaction under pressure, this allows for more space in
the matrix for cells to infiltrate and proliferate. By increasing proliferation, the amount of
ECM produced by the cells will increase and will eventually lead to a stronger gel.
Ultimately, a stronger gel would be closer to mimicking the native aortic valve leaflet.
Overall, collagen gels are an exciting underdeveloped alternative material for use in
tissue engineering.

Conclusion
Gels were pre-conditioned using biochemical factors and mechanical stimuli.
Under static conditions gels all compacted significantly over the first 2 days that indicates
a mechanism that causes gels to contract to an initial threshold. Over both test conditions
the compaction of cells seemed to stabilize after the first 48 hours. Static gels in regular
media showed the highest ultimate tensile strength; however, under pressure the strength
of these gels was greatly reduced.

Also gels in TGF-β1 did demonstrate the most

expression of MMPs under pressurized conditions. TGF-β1 did contract the most under
static conditions, but under pressure PDGF was the smallest disc. PDGF showed little
expression of MMPs under pressure and no expression under static. Contrary to the
hypothesis, PDGF showed significant change in compaction throughout the 7 day study.
The gels under pressure showed less compaction, which meant that active remodeling
was occurring. The lack of compaction is beneficial because the open space in the matrix
allows more room for cells to infiltrate. As a result of more space, cells will have more
space to proliferate, which in turn will eventually increase the overall strength of the gel
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by the increased production of ECM. Overall, collagen gels show great potential as a
scaffolding material for a tissue engineered heart valve.

Future Studies
A future study of a longer duration of the current experiment should be researched
to determine if the collagen gel strength and compaction can recuperate after an extended
exposure to cyclic pressure. Further research into the effects of various applied loads
should be investigated. For example, gels should be subjected to three-dimensional
loading via a vacuum pump system, FlexCell Tissue Train. Also, different types of
collagen (I, II ,III, IV) should be evaluated as to determine the best option for making
gels. Each type of collagen has unique properties that may have potential benefits in
manufacturing a tissue engineered heart valve. In addition, mixtures of types of collagen
should be included in the previously mentioned study.

Further research should be

conducted to determine if a better cell line exists for making collagen gels.
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CHAPTER V
CONCLUSION

Tissue engineering is an emerging field that will have major impacts on the
treatment of numerous ailments.

One of the first steps of tissue engineering an

implantable tissue is the design and fabrication of a scaffolding material. In this study,
chitosan and collagen were investigated for their potential as scaffolding material.
Chitosan was found to be a material with many advantageous qualities including
biocompatibility and biodegradation. The ease of processing and the abundant supply of
chitosan make this material an enticing option for tissue engineering. However, for an
application in the engineering of a heart valve chitosan still needs further investigation.
The need to increase strength of the scaffold and increase the amount of viable cells are
current limitations. With further exploration chitosan could possibly be an invaluable
material in tissue engineering.
Collagen gels were pre-conditioned and assessed. Under pressure or mechanical
stimuli gels expressed MMPs, which indicate remodeling activity.

Also, media

supplemented with growth factors effected the compaction of collagen gels. Samples
exposed to cyclic pressure did not compact as rapidly as gels under static conditions. The
lack of compaction leads to a more spacious matrix, which allowed for an increase in cell
infiltration and proliferation.

Collagen gels as scaffolding material showed great

potential and should be further examined.
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Overall, chitosan and collagen are exciting materials for use as scaffolds in a
tissue engineered heart valve. Both have properties that make for an ideal substrate for
numerous tissue engineering applications. With more exploration and optimization these
materials could make the goal of engineering a heart valve a reality.
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